SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer von Abrams, Tinya J, Lee, Leslie B, Murray, Lesley J, Pryer, Nancy K, Cherrington, Julie M

Volltext

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease von Fiedler, Walter, Serve, Hubert, Döhner, Hartmut, Schwittay, Michael, Ottmann, Oliver G., O'Farrell, Anne-Marie, Bello, Carlo L., Allred, Randy, Manning, William C., Cherrington, Julie M., Louie, Sharianne G., Hong, Weiru, Brega, Nicoletta M., Massimini, Giorgio, Scigalla, Paul, Berdel, Wolfgang E., Hossfeld, Dieter K.

Volltext

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of... von MENDEL, Dirk B, LAIRD, A. Douglas, MURRAY, Lesley J, CARVER, Jeremy, CHAN, Emily, MOSS, Katherine G, HAZNEDAR, Joshua Ö, SUKBUNTHERNG, Juthamas, BLAKE, Robert A, LI SUN, CHO TANG, MILLER, Todd, XIAOHUA XIN, SHIRAZIAN, Sheri, MCMAHON, Gerald, CHERRINGTON, Julie M, LOUIE, Sharianne G, CHRISTENSEN, James G, GUANGMIN LI, SCHRECK, Randall E, ABRAMS, Tinya J, NGAI, Theresa J, LEE, Leslie B

Volltext

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo von O'Farrell, Anne-Marie, Abrams, Tinya J., Yuen, Helene A., Ngai, Theresa J., Louie, Sharianne G., Yee, Kevin W.H., Wong, Lily M., Hong, Weiru, Lee, Leslie B., Town, Ajia, Smolich, Beverly D., Manning, William C., Murray, Lesley J., Heinrich, Michael C., Cherrington, Julie M.

Volltext

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer... von Abrams, Tinya J, Murray, Lesley J, Pesenti, Enrico, Holway, Vicky Walker, Colombo, Tina, Lee, Leslie B, Cherrington, Julie M, Pryer, Nancy K

Volltext

A selective small molecule inhibitor of c-Met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo von CHRISTENSEN, James G, SCHRECK, Randall, LIPSON, Kenneth E, RAMPHAL, John, DO, Steven, CUI, Jingrong J, CHERRINGTON, Julie M, MENDEL, Dirk B, BURROWS, Jon, KURUGANTI, Poonam, CHAN, Emily, PHUONG LE, CHEN, Jeffrey, XUEYAN WANG, RUSLIM, Lany, BLAKE, Robert

Volltext

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients von O'FARRELL, Anne-Marie, FORAN, James M, HEINRICH, Michael C, BERDEL, Wolfgang E, BELLO, Carlo, JACOBS, Mark, SCIGALLA, Paul, MANNING, William C, KELSEY, Stephen, CHERRINGTON, Julie M, FIEDLER, Walter, SERVE, Hubert, PAQUETTE, Ron L, COOPER, Maureen A, YUEN, Helene A, LOUIE, Sharianne G, KIM, Heidi, NICHOLAS, Susan

Volltext

Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies von LONDON, Cheryl A, HANNAH, Alison L, MENDEL, Dirk B, MCMAHON, Gerald, CHERRINGTON, Julie M, ZADOVOSKAYA, Regina, CHIEN, May B, KOLLIAS-BAKER, Cynthia, ROSENBERG, Mona, DOWNING, Sue, POST, Gerald, BOUCHER, Joseph, SHENOY, Narmada

Volltext

CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back von Mendel, Dirk B, Cherrington, Julie M, Laird, A Douglas

Volltext

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 von Potapova, Olga, Laird, A Douglas, Nannini, Michelle A, Barone, Angela, Li, Guangmin, Moss, Katherine G, Cherrington, Julie M, Mendel, Dirk B

Volltext

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model von Murray, Lesley J, Abrams, Tinya J, Long, Kelly R, Ngai, Theresa J, Olson, Lisa M, Hong, Weiru, Keast, Paul K, Brassard, Jacqueline A, O'Farrell, Anne Marie, Cherrington, Julie M, Pryer, Nancy K

Volltext

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents von Laird, A Douglas, Cherrington, Julie M

Volltext

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase von Yee, Kevin W.H., O'Farrell, Anne Marie, Smolich, Beverly D., Cherrington, Julie M., McMahon, Gerald, Wait, Cecily L., McGreevey, Laura S., Griffith, Diana J., Heinrich, Michael C.

Volltext

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity von Patyna, Shem, Laird, A Douglas, Mendel, Dirk B, O'farrell, Anne-Marie, Liang, Chris, Guan, Huiping, Vojkovsky, Tomas, Vasile, Stefan, Wang, Xueyan, Chen, Jeffrey, Grazzini, Maren, Yang, Cheng Y, Haznedar, Joshua O, Sukbuntherng, Juthamas, Zhong, Wei-Zhu, Cherrington, Julie M, Hu-Lowe, Dana

Volltext

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts von Smolich, Beverly D., Yuen, Helene A., West, Kristina A., Giles, Francis J., Albitar, Maher, Cherrington, Julie M.

Volltext

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells von Yee, Kevin W.H., Schittenhelm, Marcus, O'Farrell, Anne-Marie, Town, Ajia R., McGreevey, Laura, Bainbridge, Troy, Cherrington, Julie M., Heinrich, Michael C.

Volltext

The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function von MENDEL, Dirk B, SCHRECK, Randall E, WEST, David C, GUANGMIN LI, STRAWN, Laurie M, TANCIONGCO, Sheila S, VASILE, Stefan, SHAWVER, Laura K, CHERRINGTON, Julie M

Volltext

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification von DePrimo, Samuel E, Wong, Lily M, Khatry, Deepak B, Nicholas, Susan L, Manning, William C, Smolich, Beverly D, O'Farrell, Anne-Marie, Cherrington, Julie M

Volltext

The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation von Ning, Shoucheng, Laird, Douglas, Cherrington, Julie M., Knox, Susan J.

Volltext

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes von Giles, Francis J., Stopeck, Alison T., Silverman, Lewis R., Lancet, Jeffrey E., Cooper, Maureen A., Hannah, Alison L., Cherrington, Julie M., O'Farrell, Anne-Marie, Yuen, Helene A., Louie, Sharianne G., Hong, Weiru, Cortes, Jorge E., Verstovsek, Srdan, Albitar, Maher, O'Brien, Susan M., Kantarjian, Hagop M., Karp, Judith E.

Volltext